Chapter 104 Acute and Chronic Myeloid Leukemia (Part 3) pps
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 3) pps
... Continuous activation of Flt3 and downstream target kinases, including signal transducer and Chapter 104. Acute and Chronic Myeloid Leukemia (Part 3) Immunophenotype and Relevance to the WHO ... associated with younger age are t(8;21) and t(l5;17); with older age, del(5q) and del(7q). Myeloid sarcomas (see below) are associated with t(8;21) and disseminated intravascular coagulation ... for separating AML from acute lymphoblastic leukemia (ALL) and identifying some types of AML. For example, AML that is minimally differentiated (immature morphology and no lineage-specific...
- 5
- 250
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 1) ppsx
... the past by the Food and Drug Administration (FDA) for marketing based on trials using the FAB criteria. Acute Myeloid Leukemia Incidence The incidence of acute myeloid leukemia (AML) is ~3.7 ... years after exposure, and affected individuals have aberrations in chromosomes 5 and 7. Topoisomerase II inhibitor–associated leukemias occur 1–3 years after exposure, and affected individuals ... Chemical and Other Exposures Exposure to benzene, a solvent used in the chemical, plastic, rubber, and pharmaceutical industries, is associated with an increased incidence of AML. Smoking and exposure...
- 5
- 300
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 4) pps
... morphologically by abnormal lobulation and deficient granulation. Figure 104- 1 Chapter 104. Acute and Chronic Myeloid Leukemia (Part 4) Clinical Presentation Symptoms Patients with AML most ... they are, myeloid lineage is virtually certain (Fig 104- 1). Poor neutrophil function may be noted by impaired phagocytosis and migration and morphologically by abnormal lobulation and deficient ... anemia. The median presenting leukocyte count is about 15,000/µL. Between 25 and 40% of patients have counts <5000/µL, and 20% have counts >100,000/µL. Fewer than 5% have no detectable leukemic...
- 5
- 281
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 6) pps
... achievement of CR. In addition, patients who achieve Chapter 104. Acute and Chronic Myeloid Leukemia (Part 6) Most patients are anemic and thrombocytopenic at presentation. Replacement of ... t(6;9), inv (3), or 7 have a very poor prognosis. This emphasizes the importance of cytogenetic as well as the previously discussed molecular assessment of the leukemia cells at diagnosis and relevance ... entering CR, the length of CR, and the curability of AML. CR is defined after examination of both blood and bone marrow. The blood neutrophil count must be ≥1000/µL and the platelet count ≥100,000/µL....
- 5
- 299
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 11) pps
... Chapter 104. Acute and Chronic Myeloid Leukemia (Part 11) Chronic Myelogenous Leukemia Incidence The incidence of chronic myelogenous leukemia (CML) is 1.5 per ... transition from a chronic phase to an accelerated phase and on to blast crisis in a median time of 4 years. Etiology No clear correlation with exposure to cytotoxic drugs has been found, and no evidence ... structural alterations of the p53 gene, as well as structural alterations and lack of protein production of the retinoblastoma gene and the catalytic component of telomerase, have been associated with...
- 5
- 295
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 2) pot
... Acute myelomonocytic leukemia Acute monoblastic and monocytic leukemia Acute erythroid leukemia Acute megakaryoblastic leukemia Acute basophilic leukemia Acute panmyelosis ... myelofibrosis Myeloid sarcoma French-American-British (FAB) Classificationc Incidence M0: Minimally differentiated leukemia 5% M1: Myeloblastic leukemia without maturation 20% M2: Myeloblastic leukemia ... Myelomonocytic leukemia 20% M4Eo: Variant: Increase in abnormal marrow eosinophils M5: Monocytic leukemia 10% M6: Erythroleukemia (DiGuglielmo's disease) 4% M7: Megakaryoblastic leukemia...
- 5
- 261
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 5) docx
... Chapter 104. Acute and Chronic Myeloid Leukemia (Part 5) Morphology of AML cells. A. Uniform population of primitive myeloblasts with immature chromatin, nucleoli in some cells, and ... Ecchymosis and oozing from IV sites (DIC, possible acute promyelocytic leukemia) Fever and tachycardia (signs of infection) Papilledema, retinal infiltrates, cranial nerve abnormalities (CNS leukemia) ... patients and cryopreserved for future use as new tests and therapeutics become available. All patients should be evaluated for infection. Table 104- 2 Initial Diagnostic Evaluation and Management...
- 6
- 255
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 7) pot
... Chapter 104. Acute and Chronic Myeloid Leukemia (Part 7) Acute Myeloid Leukemia: Treatment Treatment of the newly diagnosed patient ... allogeneic stem cell Figure 104- 2 Flow chart for the therapy of newly diagnosed acute myeloid leukemia. For all forms of AML except acute promyelocytic leukemia (APL), standard therapy includes ... synthesis and thereby overcome resistance to standard-dose cytarabine. In two randomized studies, high-dose cytarabine with an anthracycline produced CR rates similar to those achieved with standard...
- 5
- 284
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 8) pdf
... Chapter 104. Acute and Chronic Myeloid Leukemia (Part 8) The hematologic toxicity of high-dose cytarabine-based induction ... been greater than that associated with 7 and 3 regimens. Toxicity with high-dose cytarabine includes myelosuppression, pulmonary toxicity, and significant and occasionally irreversible cerebellar ... each dose, and further high-dose cytarabine should be withheld if evidence of cerebellar toxicity develops. This toxicity occurs more commonly in patients with renal impairment and in those...
- 5
- 240
- 0
Chapter 104. Acute and Chronic Myeloid Leukemia (Part 9) pptx
... (SGN 33), anti-DR4, anti-DR5, anti-KiR Toxin-conjugated antibodies Gemtuzumab ozogamicin (Mylotarg) Radiolabeled antibodies Yttrium-90-labeled human M195 Chapter 104. Acute and Chronic ... cytarabine is more effective than standard-dose cytarabine. The Cancer and Leukemia Group B (CALGB), for example, compared the duration of CR in patients randomly assigned postremission to four ... Yttrium-90-labeled human M195 Chapter 104. Acute and Chronic Myeloid Leukemia (Part 9) Treatment of Promyelocytic Leukemia Tretinoin is an oral drug that induces the differentiation...
- 5
- 289
- 0
Từ khóa: Báo cáo thực tập tại nhà thuốc tại Thành phố Hồ Chí Minh năm 2018Nghiên cứu sự biến đổi một số cytokin ở bệnh nhân xơ cứng bì hệ thốngMột số giải pháp nâng cao chất lượng streaming thích ứng video trên nền giao thức HTTPNghiên cứu vật liệu biến hóa (metamaterials) hấp thụ sóng điện tử ở vùng tần số THzđề thi thử THPTQG 2019 toán THPT chuyên thái bình lần 2 có lời giảiGiáo án Sinh học 11 bài 13: Thực hành phát hiện diệp lục và carôtenôitGiáo án Sinh học 11 bài 13: Thực hành phát hiện diệp lục và carôtenôitĐỒ ÁN NGHIÊN CỨU CÔNG NGHỆ KẾT NỐI VÔ TUYẾN CỰ LY XA, CÔNG SUẤT THẤP LPWANPhối hợp giữa phòng văn hóa và thông tin với phòng giáo dục và đào tạo trong việc tuyên truyền, giáo dục, vận động xây dựng nông thôn mới huyện thanh thủy, tỉnh phú thọNghiên cứu về mô hình thống kê học sâu và ứng dụng trong nhận dạng chữ viết tay hạn chếNghiên cứu khả năng đo năng lượng điện bằng hệ thu thập dữ liệu 16 kênh DEWE 5000Tìm hiểu công cụ đánh giá hệ thống đảm bảo an toàn hệ thống thông tinSở hữu ruộng đất và kinh tế nông nghiệp châu ôn (lạng sơn) nửa đầu thế kỷ XIXBT Tieng anh 6 UNIT 2Tăng trưởng tín dụng hộ sản xuất nông nghiệp tại Ngân hàng Nông nghiệp và Phát triển nông thôn Việt Nam chi nhánh tỉnh Bắc Giang (Luận văn thạc sĩ)Giáo án Sinh học 11 bài 15: Tiêu hóa ở động vậtGiáo án Sinh học 11 bài 14: Thực hành phát hiện hô hấp ở thực vậtTrách nhiệm của người sử dụng lao động đối với lao động nữ theo pháp luật lao động Việt Nam từ thực tiễn các khu công nghiệp tại thành phố Hồ Chí Minh (Luận văn thạc sĩ)Chiến lược marketing tại ngân hàng Agribank chi nhánh Sài Gòn từ 2013-2015TÁI CHẾ NHỰA VÀ QUẢN LÝ CHẤT THẢI Ở HOA KỲ